Andrew Ambrosy to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Andrew Ambrosy has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
Connection Strength
1.101
-
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study. J Am Heart Assoc. 2021 10 19; 10(20):e020377.
Score: 0.683
-
Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE). Am Heart J. 2021 05; 235:54-64.
Score: 0.163
-
Statin Therapy and Risk of Incident Diabetes Mellitus in Adults With Cardiovascular Risk Factors. Am J Cardiol. 2020 02 15; 125(4):534-541.
Score: 0.150
-
Lipids, statins, and clinical outcomes in heart failure: rethinking the data. Heart Fail Rev. 2014 Nov; 19(6):695-8.
Score: 0.106